aspirin · Plx Pharma · NDA 203697
Vazalore
Earliest generic entry, as listed · earliest of 2 marketed strengths
29 Sep 2032
Blocked by patent: US 10646431, US 10786444, US 9216150, US 9226892, US 9226892, US 9226892.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10646431 | product | 29 Sep 2032 |
| US 10786444 | use U-3559 | 29 Sep 2032 |
| US 9216150 | product | 29 Sep 2032 |
| US 9226892 | use U-1732 | 29 Sep 2032 |
| US 9226892 | use U-1731 | 29 Sep 2032 |
| US 9226892 | use U-1733 | 29 Sep 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 203697 · 001 · RLD | capsule, oral | 325MG | 29 Sep 2032 |
| 203697 · 002 · RLD | capsule, oral | 81MG | 29 Sep 2032 |